Cormorant Asset Management, LP Galecto, Inc. Transaction History

Cormorant Asset Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.3 - $3.58 $300,131 - $467,161	-130,492 Reduced 11.34%	1,020,238 $3.09 Million
Q3 2021 Nov 15, 2021	SELL	$3.59 - $5.0 $2.17 Million - $3.02 Million	-603,109 Reduced 34.39%	1,150,730 $4.13 Million
Q2 2021 Aug 16, 2021	SELL	$4.63 - $8.0 $1.84 Million - $3.18 Million	-396,893 Reduced 18.45%	1,753,839 $8.87 Million
Q4 2020 Feb 16, 2021	BUY	$12.51 - $16.84 $26.9 Million - $36.2 Million	2,150,732 New	2,150,732 $26.5 Million

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $131M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.